A major consumer advocacy organization began consistently criticizing foes of pharmaceutical manufacturers after the industry’s top trade association directed large donations its way, a Washington ...

Stephen Ubl, chief executive of the Pharmaceutical Research and Manufacturers of America, the trade group for branded drugmakers, is stepping down at the end of the year after a decade at the ...

In a decision that bodes well for the Biden administration’s push to rein in drug prices, a federal judge in Texas has tossed (PDF) a lawsuit from industry lobbying group PhRMA which challenged the ...

Federal judge permanently blocks North Dakota 340B drug law, ruling it unconstitutional and halting enforcement against ...

PhRMA CEO Stephen J. Ubl joins CNBC's Caroline Woods at the second annual Invest in America Forum to discuss drug prices, clinical trial processes, and more.

PhRMA is again turning up the heat on both big insurance companies and their pharmacy benefit managers (PBMs) in a new ad highlighting middlemen that “own it all.” Healthcare consolidation—where big ...

Steve Ubl will step down as president and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA) at the end of 2026, the leading pharmaceutical trade group announced Wednesday. Ubl ...

Today, the district court for the Western District of Texas granted the government’s motion to dismiss the lawsuit brought by PhRMA and other organizations challenging the Drug Price Negotiation ...

WASHINGTON, July 13 (Reuters) - The U.S. drug industry named a top corporate lobbyist on Tuesday to head its trade association, a move that analysts said could mean a tougher approach on healthcare ...

More than a year after the pharmaceutical and biotech trade groups began voicing their opinions and crafting the next iteration of the US Food and Drug Administration’s (FDA) Prescription Drug User ...

On February 16, 2024, the U.S. District Court for the District of Oregon issued a ruling in Pharmaceutical Research and Manufacturers of America (PhRMA) v. Stolfi, granting in part PhRMA’s motion for ...